Sensitivity
0.8809 proportion
- EndpointStandalone suspicious-exam triage classification
- Population806 women; 403 biopsy-proven malignancy and 403 benign/negative reference cases
- Tested versionCogNet AI-MT+
FDA-cleared profile
Medcognetics, Inc. · Mammography/DBT · FDA-cleared (510(k))
Authorized purpose: Prioritizes suspicious screening DBT examinations for MQSA interpreting physicians; every examination remains subject to full physician review.
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: Prioritizes suspicious screening DBT examinations for MQSA interpreting physicians; every examination remains subject to full physician review.
Evidence takeaway. Evidence from the reviewed source record: The FDA summary reports a standalone retrospective diagnostic-enriched DBT study; no general-population screening performance claim is made.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
Packet wording: "The MedCognetics CogNet AI-MT+ software is a passive notification for prioritization- only, parallel-workflow software tool used by MQSA qualified interpreting physicians to prioritize patients with suspicious findings" … "to analyze DBT screening mammograms and flags those that are suggestive of the presence of at least one suspicious finding at the exam level. CogNet AI-MT+ produces an exam level output to a PACS/Workstation for flagging the suspicious study and allows for worklist prioritization.". Read from the exact FDA decision document on 2026-11-14.
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.
The exact device description states that the software tool is for MQSA interpreting physicians reading mammograms.
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Standalone retrospective endpoint; study context applies.
Standalone retrospective endpoint; study context applies.
0.8809 proportion
0.9156 proportion
K252482
Not representative of screening prevalence.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Price not public here; enter your quote
Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: Four bilateral DICOM For Presentation DBT views from Hologic Selenia Dimensions; validation excluded breast implants and post-surgical studies.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-19 · FDA K252482: CogNet AI-MT+
Source context, not route validation: Input may be routed from PACS, modality or a DICOM router; output may populate an API worklist column.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-05 · CogNet AI-MT+: K252482 clearance and 510(k) summary
Source context, not route validation: Cloud-based licensed access is described in the summary.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-05 · CogNet AI-MT+: K252482 clearance and 510(k) summary
Source context, not route validation: DICOM Secondary Capture and private DICOM tags with Suspicious/red-diamond or Processed/blue-circle status; no diagnostic viewer is supplied.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-19 · FDA K252482: CogNet AI-MT+
Unresolved route: DICOM Secondary Capture and private DICOM tags with Suspicious/red-diamond or Processed/blue-circle status; no diagnostic viewer is supplied.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-19 · FDA K252482: CogNet AI-MT+
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The vendor's embedded AI material is labeled investigational and is not treated as a cleared deployment capability for CogNet AI-MT+.
product family · checked 2026-09-05Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
No stored literature or trial candidates; empty metadata snapshots were screened. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Bounded web search on 2026-10-26 (query: "MedCognetics mammography AI reimbursement"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. No result was a vendor or payer page naming this product with coding or payment; any results were general billing guidance. This records what was found, not that none exists.
Technical controls in the summary do not establish a current formal security attestation.
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
8 sources - 3 history items
Scope: purpose, modality, anatomy, input, output, limitations, intendedUsers, evidenceSummary, clinicalUse
Scope: regulatoryIdentity, modalityContext
Scope: intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: recallDiscovery, nativeSubmissionMatching
Scope: identity, clinical, implementation, evidence
Scope: product_family_scope_limit
Regulatory record
510(k)
Research record
fda record reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Neurocareai, Inc. (Dba Savelife.Ai)
Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.
VinBigData Joint Stock Company
The VinDr-Mammo is a passive notification for prioritization-only, a parallel- workflow software tool used by MQSA qualified interpreting physicians to prioritize patients with suspicious findings in the medical care environment. VinDr-Mammo utilizes an artificial intelligence algorithm to analyze 2D FFDM screening mammograms and flags those that are suggestive of the presence of at least one suspicious finding at the exam- level. VinDr-Mammo produces an exam-level output to a PACS/Workstation for flagging the suspicious case and allows worklist prioritization. MQSA qualified interpreting physicians are responsible for reviewing each exam on a display approved for use in mammography, according to the current standard of care. VinDr-Mammo device is limited to the categorization of exams, does not provide any diagnostic information beyond triage and prioritization, does not remove images from the interpreting physician’s worklist, and should not be used in lieu of full patient evaluation, or relied upon to make or confirm diagnosis. The VinDr-Mammo device is intended for use with complete 2D FFDM mammography exams acquired using validated FFDM systems only.
MedCognetics, Inc.
Authorized purpose: Passive exam-level notification and prioritization of suspicious findings in screening mammograms.
DeepHealth, Inc.
Authorized purpose: Provides passive worklist prioritization for compatible FFDM and DBT screening mammograms.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history